AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9885179
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg acetylsalicylic acid (ASA) + 2 x 200 mg dipyridamole
Trial: 8279943
Drug: PAF antagonist
RxNorm normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAF antagonist Ro 24‐4736, 10 mg orally
Trial: 3569338
Drug: 150 mCi
RxNorm normalized name: samarium Sm 153 lexidronam 150 mCi/3 mL (5,550 MBq/3 mL) INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mCi 131I (therapeutic dose for all patients)
Trial: 29784451
Drug: 60 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm)
Trial: 15185427
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (11 microg twice weekly)
Trial: 11714065
Drug: Placebo cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, applied once daily for 7 days
Trial: 8237866
Drug: Two FeSO4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two FeSO4 tablets (100 mg Fe) daily
Trial: 8237866
Drug: One GDS
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One GDS capsule (50 mg Fe) daily
Trial: 8237866
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron supplement
Trial: 2897260
Drug: GHRH administration
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administration in all groups
Trial: 2897260
Drug: GHRH administration
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administration in untreated control women
Trial: 26012780
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with Staphylococcus epidermidis applied to the face twice per week for four weeks
Trial: 24265159
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of MTX/6MP
Trial: 24265159
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of MTX/6MP
Trial: 21750293
Drug: BAL-directed therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL-directed therapy (n = 84)
Trial: 21750293
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 86)
Trial: 15041599
Drug: Sufentanil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plus methylprednisolone 10 microg plus 40 mg
Trial: 11149478
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g daily)
Trial: 30987432
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg 3 times/d and hydration)
Trial: 29696915
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Adalat 30 mg at 7 am daily for 6 weeks)
Trial: 29696915
Drug: No.1 acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No.1 acupuncture group (acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen, in addition to medication)
Trial: 29696915
Drug: No.2 acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No.2 acupuncture group (additional acupuncture at Fengchi (GB 20) and Neck‐Jiaji (EX‐B 2) on top of No.1 acupuncture group treatment)
Trial: 12145715
Drug: Mupirocin nasal
RxNorm normalized name: mupirocin Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin nasal ointment applied twice daily from admission to surgery
Trial: 12145715
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal ointment applied twice daily from admission to surgery
Trial: 12145715
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal ointment
Trial: 9990598
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy (i.v. procainamide)
Trial: 8520806
Drug: Diclofenac dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac dispersible 46.5 mg (equivalent to 50 mg of diclofenac sodium)
Trial: 2315431
Drug: Sibutramine HCl
RxNorm normalized name: SIBUTRAMINE HCL 5MG CAP
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine HCl (15 mg twice daily)
Trial: 2315431
Drug: Sibutramine HCl
RxNorm normalized name: SIBUTRAMINE HCL 5MG CAP
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine HCl (single dose of 12.5 or 50 mg)
Trial: 2315431
Drug: Sibutramine HCl
RxNorm normalized name: SIBUTRAMINE HCL 5MG CAP
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine HCl (5‐20 mg once daily)
Trial: 6968220
Drug: Indometacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (200 mg daily)
Trial: 6968220
Drug: Acemetacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (200 mg daily)
Trial: 6968220
Drug: Acemetacin (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (240 mg daily)
Trial: 21840055
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (specific statins not detailed)
Trial: 21840055
Drug: Nonadherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadherence to medication
Trial: 21840055
Drug: Beliefs about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beliefs about medicines (assessed using BMQ-G)
Trial: 11878726
Drug: Ropivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 150 mg (7.5 mg ml(‐1))
Trial: 11878726
Drug: Ropivacaine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 100 mg (5 mg ml(‐1))
Trial: 11878726
Drug: Ropivacaine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 200 mg (10 mg ml(‐1))
Trial: 11878726
Drug: Bupivacaine 100
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 100 mg (5 mg ml(‐1))
Trial: 2744356
Drug: Pentagastrin injection
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentagastrin injection
Trial: 333606
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and intraoperative antibiotics
Trial: 30904875
Drug: Pterygopalatine ganglion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pterygopalatine ganglion pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds
Trial: 30904875
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block (NB) treatment with a mixture of steroids and local anaesthetics
Trial: 20499024
Drug: Combination (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (500 mg vitamin C and 200 mg Tocovid)
Trial: 20499024
Drug: Tocotrienol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocotrienol (200 mg)
Trial: 1754635
Drug: ritanserin (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritanserin (5-10 mg)
Trial: 6923655
Drug: Calcium heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin, 5000 IU s.c. every 8 hr for 7 days, first administration 2 hr before surgery
Trial: 6709383
Drug: Imaginal strategy
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imaginal strategy treatment (response group) - trained to imagine pleasant scenes including muscular relaxation and deep breathing.
Trial: 6709383
Drug: Imaginal strategy
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imaginal strategy treatment (stimulus group) - trained to imagine scenes with many stimulus details.
Trial: 31852846
Drug: RN168 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RN168 1 mg/kg every other week (Q2wk)
Trial: 31852846
Drug: RN168 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RN168 3 mg/kg every other week (Q2wk)
Trial: 31852846
Drug: RN168 higher
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RN168 higher doses (not specified)
Trial: 26863596
Drug: Aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminolevulinic acid photodynamic therapy (ALA‐PDT)
Trial: 26863596
Drug: Vehicle photodynamic
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle photodynamic therapy (VEH‐PDT)
Trial: 24997559
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg for participants ≥18 years, 50 mg for those <18 years) and Lansoprazole (60 mg for participants ≥18 years, 30 mg for those <18 years)
Trial: 20139792
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily activity counts
Trial: 20139792
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily minutes of moderate to vigorous physical activity (MVPA)
Trial: 17932823
Drug: 4% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine solution
Trial: 3286393
Drug: Ritodrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine infusion
Trial: 1861962
Drug: Duraphat (2.26%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraphat (2.26% fluoride), n = 206, six-monthly applications
Trial: 1861962
Drug: Carex (1.80%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carex (1.80% fluoride), n = 189, six-monthly applications
Trial: 29846719
Drug: sucroferric oxyhydroxide
RxNorm normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucroferric oxyhydroxide 1.0-3.0 g/day
Trial: 29846719
Drug: sevelamer 2.4-14.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sevelamer 2.4-14.4 g/day
Trial: 25667293
Drug: 10% Urea-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Urea-based cream (UBC) plus best supportive care (BSC)
Trial: 19765131
Drug: Cerebrolysin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (30 ml diluted in physiologic saline) given as intravenous infusion once daily for 10 days
Trial: 19765131
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) given as intravenous infusion once daily for 10 days
Trial: 15570253
Drug: GM‐CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF plus G‐CSF
Trial: 15570253
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of G‐CSF followed by GM‐CSF 6 days later
Trial: 11148742
Drug: Alpha blocker-finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha blocker-finasteride combination therapy
Trial: 10323611
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics (bacitracin ointment applied 2-3 times daily)
Trial: 6750206
Drug: Alternate-day steroids
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day steroids (ADS)
Trial: 6750206
Drug: Daily steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily steroids (DS)
Trial: 27897989
Drug: Sleep-low strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep-low strategy (SL), CHO intake: 6 g·kg‐1·day‐1
Trial: 19485591
Drug: One-session exposure
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session exposure treatment
Trial: 18005932
Drug: Five-session exposure
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-session exposure treatment
Trial: 15732265
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 44 mcg once weekly
Trial: 15732265
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 22 mcg once weekly
Trial: 15732265
Drug: Placebo/22 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/22 mcg
Trial: 15732265
Drug: Placebo/44 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/44 mcg
Trial: 12958848
Drug: Donepezil capsule
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil capsule (5 mg)
Trial: 12958848
Drug: Donepezil tablet
RxNorm normalized name: donepezil Oral Tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil tablet (5 mg)
Trial: 12958848
Drug: Donepezil capsule
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil capsule
Trial: 10778658
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release formulation A (Tegretol CR, local)
Trial: 10778658
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release formulation B (Tegretol CR, Basel)
Trial: 10778658
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation (Tegretol)
Trial: 1428134
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Vitamin K intramuscular (Menadione sodium disulphite) at birth
Trial: 1428134
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Vitamin K intramuscular
Trial: 1428134
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Vitamin K orally
Trial: 3883857
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline 1 mg in 2 mL normal saline
Trial: 3883857
Drug: Subcutaneous epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous epinephrine 0.01 mg/kg (0.3 mg maximum)
Trial: 28580884
Drug: MI-CBT (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-CBT (Motivational Interviewing integrated with Cognitive-Behavioral Therapy)
Trial: 30140707
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of blood glucose (BG) < 3.9 mmol/L
Trial: 30140707
Drug: Area under
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Area under the curve for BG > 7.8 mmol/L
Trial: 20370945
Drug: Lactulose in
RxNorm normalized name: Product containing lactulose in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose in liquid (L-L)
Trial: 20370945
Drug: Solid lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solid lactulose (L-S)
Trial: 14583173
Drug: Hypoglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic clamp (approximately 50 mg/dl)
Trial: 14583173
Drug: Euglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemic clamp (approximately 90 mg/dl)
Trial: 10572207
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 mg via Aerolizer
Trial: 10572207
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 mg via Turbuhaler
Trial: 8949363
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g within 60 min)
Trial: 8501156
Drug: Bombesin (BBS)
RxNorm normalized name: Dream Pure BB
DrugBank: Bombesin (DB11724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bombesin (BBS) infusion
Trial: 8501156
Drug: Loxiglumide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide treatment alone
Trial: 3123598
Drug: Deprenyl 5
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl 5 mg BID
Trial: 29604160
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg/d for 6 weeks
Trial: 26121892
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine (5 mg/kg in 2 cc/kg apple juice)
Trial: 26121892
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 cc/kg apple juice)
Trial: 20209968
Drug: Xianling Gubao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xianling Gubao capsules
Trial: 7925516
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (10 mg quinapril plus 12.5 mg HCTZ)
Trial: 7925516
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 10 mg quinapril
Trial: 7925516
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 12.5 mg HCTZ
Trial: 2509737
Drug: Tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-type plasminogen activator at a dose of 0.05 mg/kg/hr (n = 4)
Trial: 2509737
Drug: Tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-type plasminogen activator at a dose of 0.025 mg/kg/hr (n = 4)
Trial: 2509737
Drug: Tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-type plasminogen activator (both doses)
Trial: 17950970
Drug: Fluoxetine (10-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10-60 mg/d)
Trial: 17950970
Drug: Sertraline (25-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25-350 mg/d)
Trial: 16029334
Drug: Calcipotriol scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol scalp solution 50 microg mL(‐1) applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Trial: 16029334
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Trial: 16029334
Drug: Combined results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined results of treatment groups (calcipotriol and vehicle).
Trial: 10589631
Drug: Ropivacaine 2
RxNorm normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 2 mg/mL
Trial: 10656057
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g gamma‐CD (test)
Trial: 10656057
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g maltodextrin (placebo)
Trial: 2192462
Drug: Daily injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injections of growth hormone (0.3 mg/kg weekly)
Trial: 2192462
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times weekly injections of growth hormone (0.3 mg/kg weekly)
Trial: 2192462
Drug: Once a
RxNorm normalized name: Once A Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a week injections of growth hormone (0.3 mg/kg weekly)
Trial: 2192462
Drug: Daily injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injections of growth hormone (after switching from once or three times a week)
Trial: 24613523
Drug: BioThrax® (anthrax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioThrax® (anthrax vaccine adsorbed) administered subcutaneously (SC) in a three-dose regimen (0, 2, and 4 weeks)
Trial: 27178435
Drug: Bitopertin 30
RxNorm normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitopertin 30 mg
Trial: 22980315
Drug: Bitopertin 175
RxNorm normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitopertin 175 mg
Trial: 15226466
Drug: Isoflavones from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones from red clover-derived dietary supplement (43.5 mg/d)